The nation of Zimbabwe has rejected a major US healthcare agreement worth $367m (£272m) over five years because of the United States' insistence on confidential biological samples.
This move came to light after a internal memorandum from December was disclosed, which showed Head of State Emmerson Mnangagwa believed the agreement was "lopsided".
An official spokesperson has since stated that the United States was requesting health data for research and commercial purposes but refused to share the resulting advantages from future treatments.
"We are forced to start the difficult and regrettable task of winding down our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had donated more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has appealed for more negotiations to secure a deal agreeable to all parties so the nation's critical HIV treatment initiative can be sustained.
Broader Implications
This development comes after a similar situation in Kenya, where a high court blocked a similar deal with the US following concerns were raised about the safety of Kenyans' health data.
Since resuming office recently, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
USAID had managed aid for the American government, but Trump claimed its expenditure was "inefficient" and his government was seeking government-to-government agreements to enhance openness and responsibility.
Based on reports, 16 African countries have to date agreed to similar agreements, constituting more than $18.3bn of fresh investment.
Specifics of the Rejected Deal
The money for Zimbabwe was intended to funded "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this partnership would have delivered immense benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently receiving HIV treatment through American-funded programmes," Tremont commented.
However, official spokesman Nick Mangwana said the proposed deal was "asymmetrical".
"Zimbabwe was being asked to share its biological resources and data indefinitely, without any equivalent assurance of access to any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that shared data," Mangwana explained.
"Put simply, our nation would provide the raw materials for scientific discovery with no certainty that the final treatments would be accessible to our citizens should a new health crisis emerge."
National Interest and International Frameworks
Mangwana further pointed out that the US's withdrawal from the global health body and its push of bilateral health agreements were undermining structures already established via the global organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme created to deal with future pandemics.
"This framework is intended to guarantee that when a nation provides its data, the benefits – such as vaccines and treatments – are distributed fairly, not commercialised solely by those with the funds to create them."
These objections over the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We encourage continued dialogue with our American counterparts on how future collaboration could be arranged in a way that honours the independence and dignity of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it recognised the official position, but recommended that talks should continue since a large portion of the nation's HIV programmes were funded by foreign aid.
"If specific concerns arise, such as those involving information security or implementation frameworks, these can often be resolved via detailed discussion and negotiated safeguards," the group added.
This impasse highlights the ongoing tensions between receiving vital international aid and safeguarding national sovereignty in an increasingly data-driven world.